Scott Lipnick

Scott Lipnick joined Flagship Pioneering in 2021. As an origination partner, he leads a team of entrepreneurs responsible for originating and growing Preemptive Health and Medicine. These companies focus on detecting and intervening against major diseases before traditional clinical diagnosis or significant changes in symptomology occur.

Prior to Flagship, Scott served as the vice president of life and data science at PatientsLikeMe – initially a subsidiary of UnitedHealth Group R&D and later Optum Ventures – where his team focused on generating and analyzing real-world and multi-omics data collected from individuals at key inflection points in disease onset and progression.

Before entering industry, Scott was a faculty member at the Harvard School of Medicine, Department of Biomedical Informatics and the Massachusetts General Hospital Center for Assessment Technology and Continuous Health. He also held affiliate positions at the Broad Institute, the Harvard Stem Cell Institute and the Harvard University Department of Stem Cell and Regenerative Biology. His research aimed to extract value from data captured within insurance claims, electronic health records, and genomics using machine learning and artificial intelligence. Scott’s publications relate to advancing the understanding of disease onset and progression, identifying people at risk of disease before major clinical presentation, determining who will respond to a given intervention, and exploring druggable pathways that underlie specific forms of disease.

Scott received his B.S in Physics and Economics from Brandeis University and his Ph.D. in Biomedical Physics from the University of California, Los Angeles. Following his graduate studies, he was an AAAS Science and Technology Policy Fellow at the NIH Center for Regenerative Medicine.